561 related articles for article (PubMed ID: 24470103)
1. Elevated fibroblast growth factor 23 exerts its effects on placenta and regulates vitamin D metabolism in pregnancy of Hyp mice.
Ohata Y; Yamazaki M; Kawai M; Tsugawa N; Tachikawa K; Koinuma T; Miyagawa K; Kimoto A; Nakayama M; Namba N; Yamamoto H; Okano T; Ozono K; Michigami T
J Bone Miner Res; 2014 Jul; 29(7):1627-38. PubMed ID: 24470103
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro.
Perwad F; Zhang MY; Tenenhouse HS; Portale AA
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1577-83. PubMed ID: 17699549
[TBL] [Abstract][Full Text] [Related]
3. Eldecalcitol Causes FGF23 Resistance for Pi Reabsorption and Improves Rachitic Bone Phenotypes in the Male Hyp Mouse.
Kaneko I; Segawa H; Ikuta K; Hanazaki A; Fujii T; Tatsumi S; Kido S; Hasegawa T; Amizuka N; Saito H; Miyamoto KI
Endocrinology; 2018 Jul; 159(7):2741-2758. PubMed ID: 29878089
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic homeostasis of vitamin D metabolism in the kidney through reciprocal modulation of Cyp27b1 and Cyp24a1 expression.
Meyer MB; Pike JW
J Steroid Biochem Mol Biol; 2020 Feb; 196():105500. PubMed ID: 31629064
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of calcitriol during pregnancy and skeletal recovery after lactation do not require parathyroid hormone.
Kirby BJ; Ma Y; Martin HM; Buckle Favaro KL; Karaplis AC; Kovacs CS
J Bone Miner Res; 2013 Sep; 28(9):1987-2000. PubMed ID: 23505097
[TBL] [Abstract][Full Text] [Related]
6. FGF23 Neutralizing Antibody Ameliorates Hypophosphatemia and Impaired FGF Receptor Signaling in Kidneys of HMWFGF2 Transgenic Mice.
Du E; Xiao L; Hurley MM
J Cell Physiol; 2017 Mar; 232(3):610-616. PubMed ID: 27306296
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 23 inhibits extrarenal synthesis of 1,25-dihydroxyvitamin D in human monocytes.
Bacchetta J; Sea JL; Chun RF; Lisse TS; Wesseling-Perry K; Gales B; Adams JS; Salusky IB; Hewison M
J Bone Miner Res; 2013 Jan; 28(1):46-55. PubMed ID: 22886720
[TBL] [Abstract][Full Text] [Related]
8. Neither absence nor excess of FGF23 disturbs murine fetal-placental phosphorus homeostasis or prenatal skeletal development and mineralization.
Ma Y; Samaraweera M; Cooke-Hubley S; Kirby BJ; Karaplis AC; Lanske B; Kovacs CS
Endocrinology; 2014 May; 155(5):1596-605. PubMed ID: 24601885
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic (Hyp) mouse model.
Nakatani T; Ohnishi M; Razzaque MS
FASEB J; 2009 Nov; 23(11):3702-11. PubMed ID: 19584304
[TBL] [Abstract][Full Text] [Related]
10. Variable phosphate-mediated regulation of vitamin D metabolism in the murine hypophosphatemic rachitic/osteomalacic disorders.
Davidai GA; Nesbitt T; Drezner MK
Endocrinology; 1991 Mar; 128(3):1270-6. PubMed ID: 1999147
[TBL] [Abstract][Full Text] [Related]
11. Regulation of 25-hydroxyvitamin D-1-hydroxylase and 24-hydroxylase in keratinocytes by PTH and FGF23.
Wu W; Fan H; Jiang Y; Liao L; Li L; Zhao J; Zhang H; Shrestha C; Xie Z
Exp Dermatol; 2018 Nov; 27(11):1201-1209. PubMed ID: 30066343
[TBL] [Abstract][Full Text] [Related]
12. Vitamin D and type II sodium-dependent phosphate cotransporters.
Kido S; Kaneko I; Tatsumi S; Segawa H; Miyamoto K
Contrib Nephrol; 2013; 180():86-97. PubMed ID: 23652552
[TBL] [Abstract][Full Text] [Related]
13. Distinct roles for intrinsic osteocyte abnormalities and systemic factors in regulation of FGF23 and bone mineralization in Hyp mice.
Liu S; Tang W; Zhou J; Vierthaler L; Quarles LD
Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1636-44. PubMed ID: 17848631
[TBL] [Abstract][Full Text] [Related]
14. Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice.
Aono Y; Hasegawa H; Yamazaki Y; Shimada T; Fujita T; Yamashita T; Fukumoto S
J Bone Miner Res; 2011 Apr; 26(4):803-10. PubMed ID: 20939065
[TBL] [Abstract][Full Text] [Related]
15. Impaired Growth Plate Maturation in XLH Is due to Both Excess FGF23 and Decreased 1,25-Dihydroxyvitamin D Signaling.
Yadav PS; Kobelski MM; Martins JS; Tao T; Liu ES; Demay MB
Endocrinology; 2023 Nov; 165(1):. PubMed ID: 38066669
[TBL] [Abstract][Full Text] [Related]
16. Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutation.
Farrow EG; Summers LJ; Schiavi SC; McCormick JA; Ellison DH; White KE
J Endocrinol; 2010 Oct; 207(1):67-75. PubMed ID: 20675303
[TBL] [Abstract][Full Text] [Related]
17. Increased bone volume and correction of HYP mouse hypophosphatemia in the Klotho/HYP mouse.
Brownstein CA; Zhang J; Stillman A; Ellis B; Troiano N; Adams DJ; Gundberg CM; Lifton RP; Carpenter TO
Endocrinology; 2010 Feb; 151(2):492-501. PubMed ID: 19952276
[TBL] [Abstract][Full Text] [Related]
18. Klotho converts canonical FGF receptor into a specific receptor for FGF23.
Urakawa I; Yamazaki Y; Shimada T; Iijima K; Hasegawa H; Okawa K; Fujita T; Fukumoto S; Yamashita T
Nature; 2006 Dec; 444(7120):770-4. PubMed ID: 17086194
[TBL] [Abstract][Full Text] [Related]
19. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
Li H; Martin A; David V; Quarles LD
Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E508-17. PubMed ID: 21139072
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets.
Wöhrle S; Henninger C; Bonny O; Thuery A; Beluch N; Hynes NE; Guagnano V; Sellers WR; Hofmann F; Kneissel M; Graus Porta D
J Bone Miner Res; 2013 Apr; 28(4):899-911. PubMed ID: 23129509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
